attIL2-T
/ UT MD Anderson Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 10, 2025
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting
Enrollment closed • Oncology • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
September 15, 2023
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting | Initiation date: May 2023 ➔ Sep 2023
Enrollment open • Metastases • Trial initiation date • Oncology • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
November 18, 2022
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center
New P1 trial • Oncology • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor
1 to 3
Of
3
Go to page
1